VIFOR-PHARMA
Regulatory News:
Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharmaceutical group GlaxoSmithKline, most recently as Global President Pharmaceuticals and Vaccines for five years. Prior to that, he worked for 20 years for the U.S. pharmaceutical group Eli Lilly, holding management positions at sites in the US, Europe, Asia and Australia.
In recent years, he has contributed his experience as an independent member of the boards of directors of major pharmaceutical, biotech and medical device companies, such as Teva Pharmaceuticals, CSL and Cochlear. He has also acted as an advisor to private equity and venture capital firms focused on the healthcare sector. Abbas Hussain holds a Bachelor of Science in Medicinal and Pharmaceutical Chemistry from Loughborough Institute of Technology (UK), graduated from Duke University Fuqua Executive Business School (North Carolina, USA) and is a graduate of the Stanford Executive Program at Stanford University (California, USA).
Until Abbas Hussain joins the company on 16 August 2021, Stefan Schulze will continue to have overall executive responsibility for the Vifor Pharma Group. Stefan Schulze, who has been with Vifor Pharma for seven years, took over as CEO in March 2020. From 2017 to 2020, he was President of the Executive Committee and Chief Operating Officer (COO) of the Vifor Pharma Group. He joined the Vifor Pharma Group in 2014 as CEO of Vifor Fresenius Medical Care Renal Pharma Ltd. Prior to that, he worked for the German Fresenius Group for more than 20 years in various positions.
Jacques Theurillat, Chairman of the Board of Directors of Vifor Pharma, commented: “We are delighted that Abbas Hussain, an experienced and entrepreneurial leader, will take over the helm of Vifor Pharma. Abbas Hussain brings over 30 years of track record at an international level in the healthcare sector, and also an impressive experience across the pharmaceutical value chain in both mature and emerging markets. His professional background makes him ideally suited to further drive Vifor Pharma's growth. On behalf of the Board of Directors, I would like to thank Stefan Schulze for his commitment to Vifor Pharma over the past seven years. He has made a significant contribution to the strong market position of the Vifor Pharma Group. We wish him all the best for the future.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005916/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreviPay Powers Walmart Business Pay By Invoice Offering16.9.2025 13:00:00 CEST | Press release
TreviPay, a fully managed B2B payments platform, has collaborated with Walmart Business to launch the next phase of the retailer’s Pay By Invoice program. The program enables eligible business customers to access a line of credit with 30-day net terms, powered by TreviPay’s next-generation payments and A/R automation technology. The offering is available for purchases online, in the Walmart Business app or in-store. A study of 300 global business buyers, conducted by Murphy Research for TreviPay, found 85% of buyers want the option to pay on net terms and are likely to buy more when they can pay this way. TreviPay’s Pay by Invoice offering enables buyers to defer payment, receive detailed invoices for streamlined recordkeeping and procurement, and manage cash flow more effectively. “The biggest opportunity in retail now is in B2B. Companies that capture this valuable segment will win with flexible payment options that integrate directly into the buying experience and maintain efficienc
Areteia Therapeutics AnnouncesPositive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma16.9.2025 13:00:00 CEST | Press release
In the EXHALE-4 study, dexpramipexole met the primary endpoint with statistically significant improvement in lung function compared with placeboDexpramipexole demonstrated statistically significant reduction in blood absolute eosinophil count (AEC) compared with placeboFull results will be presented at an upcoming medical meeting; Areteia continues to enroll the EXHALE-2 and EXHALE-3 Phase III exacerbation studies of dexpramipexole in eosinophilic asthma Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with eosinophilic asthma. “More than half of people with asthma have the eosinophilic subtype, yet there remains a profound need for easily administered oral treatment options that can help address their symptoms, which are often severe,” said Ian Pavord, MA, DM, Professor of Respiratory Medicine at the University of Oxford, UK and a member of Areteia’s
NIQ Joins the Decentriq Network to Enable Secure Data Collaboration for Marketers and Agencies Across Europe16.9.2025 12:00:00 CEST | Press release
NIQ, a leading consumer intelligence company, is entering a strategic relationship with Decentriq to enable data collaboration for media use cases across Europe. Through the relationship, NIQ’s high quality consumer insights, including digital purchase data, will be available in Decentriq’s privacy-preserving clean rooms for the first time, enabling advertisers and agencies to utilize the data for audience profiling and closed loop measurement. Expanding beyond shopper insights NIQ is expanding its services to the data and media ecosystem through privacy-persevering clean rooms, opening up new opportunities for marketing and advertising agencies to enrich their first-party data insights, inform audience strategies, and measure sales outcomes. As Pierre Cholet, Chief Customer Officer at Decentriq, explains, “NIQ has long been a trusted name in understanding consumer purchasing behavior. Now, by integrating their data into Decentriq’s clean room, advertisers and agencies can leverage thi
Businesses Scale Transformation to Meet Regulatory, Technology and Customer Challenges, Finds Arthur D. Little Global Research16.9.2025 11:45:00 CEST | Press release
Transformation is now a way of life for global companies, with two-thirds (65%) undergoing wide-reaching or expanding organization-wide transformation initiatives. This is driven by regulatory change (including tariffs), technological disruption, and shifting customer needs, all of which are rated at 4.1/5 in importance. Confidence levels are high, with 95% expecting initiatives to deliver success, according to the inaugural Arthur D. Little (ADL) Global Transformation Study. Time frames vary significantly between regions. 71% have a four-to-six-year window for transformation, with 32% focused on five years. However, average timelines range from 3.2 years in North America to 4.9 years in the Middle East and 5.5 years in Asia-Pacific. There are also significant differences between who leads transformation efforts globally. While a third (32%) of companies have a Chief Transformation Officer (CTrO), adoption varies considerably by region. 53% of European companies have a CTrO, compared w
Reply Achieves the AWS Advertising and Marketing Technology Competency Thanks to the Contribution of the Data Reply and Storm Reply Teams16.9.2025 10:40:00 CEST | Press release
Reply [EXM, STAR: REY] has achieved the AWS Advertising and Marketing Technology Competency, the official recognition from Amazon Web Services certifying advanced technical and project expertise in the design and delivery of advertising and marketing solutions on AWS. This milestone was made possible thanks to the joint contribution of Storm Reply and Data Reply, both part of the Reply Group, with solid expertise in implementing cloud-native and data-driven solutions on the AWS platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916374888/en/ With this certification, Reply’s companies specialized in AWS services further consolidate their role as trusted technology partners for organizations looking to evolve their marketing and communication strategies through the advanced use of AWS cloud and AI technologies. The AWS Advertising and Marketing Technology Competency validates the ability of AWS Partners to deliver hig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom